title: MBD2 deficiency does not accelerate p53 mediated lymphomagenesis.
abstract: Recent studies using hypomorphic DNA methyltransferase 1 (DNMT1) alleles have suggested that strategies aiming to reduce DNA methylation may increase genomic instability and lymphomagenesis. Given our recent finding that loss of methyl-binding domain protein 2 (Mbd2) suppresses intestinal tumorigenesis, we have tested whether loss of Mbd2 increases lymphomagenesis by intercrossing Mbd2 deficient mice with p53 deficient and p53 heterozygous mice. Unlike DNMT1, loss of Mbd2 does not accelerate lymphomagenesis, arguing that MBD2 may represent a better potential therapeutic target than DNMT1.
authors.affiliation: Mammalian Genetics, Cardiff School of Biosciences, University of Cardiff, Museum Avenue, PO Box 911, Cardiff CF10 3US, UK.
authors.forename: Owen James
authors.initials: OJ
authors.lastname: Sansom
authors.forename: Stefan Mark
authors.initials: SM
authors.lastname: Bishop
authors.forename: Adrian
authors.initials: A
authors.lastname: Bird
authors.forename: Alan Richard
authors.initials: AR
authors.lastname: Clarke
mesh_terms: D000818:Animals; D019175:DNA Methylation; D004268:DNA-Binding Proteins / Q000235:genetics*; D008223:Lymphoma / Q000235:genetics / Q000473:pathology*; D051379:Mice; D018345:Mice, Knockout; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000502:physiology*
chemical_list: D004268:DNA-Binding Proteins; C115368:MBD2 protein; D016159:Tumor Suppressor Protein p53